|
Market Closed -
NYSE
01:30:02 16/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 166.68 USD | +2.87% |
|
+4.98% | +81.31% |
| 16/10 | Health Care Up on Safe-Haven Demand -- Health Care Roundup | DJ |
| 15/10 | European Stocks Close Higher in Thursday Trading on Strong Earnings; Investors Parse Hot US Inflation Report | MT |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,82,034 | 2,09,442 | 2,09,268 | 2,03,171 | 2,87,813 | 2,60,995 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -9.32% | - | - |
| Enterprise Value (EV) 1 | 2,06,417 | 2,32,365 | 2,31,778 | 2,27,741 | 3,11,187 | 2,80,935 | 2,73,300 | 2,65,161 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -9.72% | -2.72% | -2.98% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 22x | 18.9x | 16.9x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.83x | 4.18x | 3.59x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.3x | 1.1x | 1.4x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.12x | 3.87x | 3.66x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.43x | 4.06x | 3.71x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.7x | 11.2x | 9.91x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 13.3x | 11.8x | 10.4x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28.3x | 21.2x | 18.1x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.53% | 4.72% | 5.54% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.342 | 3.547 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.99% | 2.11% | 2.17% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.648 | 8.906 | 9.969 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.7% | 39.8% | 36.7% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,400 | 67,369 | 71,397 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,112 | 24,326 | 26,760 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,066 | 23,252 | 25,508 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,805 | 13,729 | 15,339 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,941 | 12,305 | 4,166 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 168.27 | 168.27 | 168.27 |
| Nbr of stocks (in thousands) | 15,49,159 | 15,49,528 | 15,49,926 | 15,50,317 | 15,50,726 | 15,51,024 | - | - |
| Announcement Date | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.58x | 12.46x | 26.12x | 0.57% | 1,07700Cr | |
| 37.53x | 6.26x | 17.55x | 2.1% | 61TCr | |
| 36.12x | 8.31x | 17.13x | 2.45% | 50TCr | |
| 113.84x | 6x | 25.7x | 2.32% | 36TCr | |
| 20.01x | 4.88x | 12.13x | 2.7% | 35TCr | |
| 20.46x | 5.37x | 13.21x | 2.96% | 28TCr | |
| 21.15x | 4.27x | 12.26x | 2.07% | 25TCr | |
| 27.06x | 6.97x | 12.48x | 2.37% | 23TCr | |
| -44.86x | 6.85x | 26.64x | 2.14% | 19TCr | |
| Average | 29.54x | 6.82x | 18.14x | 2.19% | 42.85TCr | |
| Weighted average by Cap. | 35.12x | 7.99x | 19.65x | 1.87% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
